315 related articles for article (PubMed ID: 31074303)
1. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers.
Soliman AM; Alqahtani AS; Ghorab M
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1030-1040. PubMed ID: 31074303
[TBL] [Abstract][Full Text] [Related]
2. Dual EGFR/HER2 inhibitors and apoptosis inducers: New benzo[g]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers.
Ghorab MM; Alsaid MS; Soliman AM
Bioorg Chem; 2018 Oct; 80():611-620. PubMed ID: 30041137
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors.
Alsaid MS; Al-Mishari AA; Soliman AM; Ragab FA; Ghorab MM
Eur J Med Chem; 2017 Dec; 141():84-91. PubMed ID: 29028534
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis, cytotoxicity and radiosensitization by novel 3,4-dihydroquinazolinone derivatives.
Soliman AM; Khalil A; Ramadan E; Ghorab MM
Bioorg Med Chem Lett; 2021 Oct; 49():128308. PubMed ID: 34363937
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
8. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
9. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
[TBL] [Abstract][Full Text] [Related]
11. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and
Le Y; Gan Y; Fu Y; Liu J; Li W; Zou X; Zhou Z; Wang Z; Ouyang G; Yan L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):555-564. PubMed ID: 31967481
[TBL] [Abstract][Full Text] [Related]
13. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
14. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
Alkamaly OM; Altwaijry N; Sabour R; Harras MF
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
[TBL] [Abstract][Full Text] [Related]
15. Novel thioureido-benzenesulfonamide derivatives with enaminone linker as potent anticancer, radiosensitizers and VEGFR2 inhibitors.
Ghorab MM; Ragab FA; Heiba HI; El-Gazzar MG; El-Gazzar MGM
Bioorg Med Chem Lett; 2018 May; 28(9):1464-1470. PubMed ID: 29628325
[TBL] [Abstract][Full Text] [Related]
16. Novel sulphonamide-bearing methoxyquinazolinone derivatives as anticancer and apoptosis inducers: synthesis, biological evaluation and
Alqahtani AS; Ghorab MM; Nasr FA; Ahmed MZ; Al-Mishari AA; Attia SM
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):86-99. PubMed ID: 34894963
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells.
Zhang Y; Wang Q; Li L; Le Y; Liu L; Yang J; Li Y; Bao G; Yan L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1205-1216. PubMed ID: 34074193
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
Aziz MW; Kamal AM; Mohamed KO; Elgendy AA
Bioorg Med Chem Lett; 2021 Jun; 41():127987. PubMed ID: 33771586
[TBL] [Abstract][Full Text] [Related]
19. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.
Ghorab MM; Alsaid MS; Soliman AM; Al-Mishari AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):67-73. PubMed ID: 29098904
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis.
El-Azab AS; Abdel-Aziz AA; AlSaif NA; Alkahtani HM; Alanazi MM; Obaidullah AJ; Eskandrani RO; Alharbi A
Bioorg Chem; 2020 Nov; 104():104345. PubMed ID: 33142413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
